Company news
Nkarta, Inc. (NASDAQ:NKTX) news
Nkarta, Inc. news releases on 6ix. Latest, Sep 10, 2026: Nkarta to Participate in September Investor Conferences
Press releases & updates
Nkarta to Participate in September Investor Conferences
September 10, 2026
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
September 8, 2026
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 10, 2026
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 26, 2026
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
May 12, 2026
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
April 14, 2026
Nkarta to Participate in Needham Virtual Healthcare Conference
April 9, 2026
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
March 24, 2026
Nkarta to Participate in Evercore Healthcare Conference
December 2, 2025
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 10, 2025
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 9, 2025
Nkarta to Participate in November Investor Conferences
October 30, 2025
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
October 22, 2025
Nkarta to Participate in a September Investor Conference
September 2, 2025
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 12, 2025
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
July 23, 2025
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
June 6, 2025
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
May 14, 2025
Nkarta to Participate in an April Investor Conference
April 1, 2025
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
March 26, 2025
Nkarta to Participate in March Investor Conferences
February 25, 2025
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
December 4, 2024
Nkarta to Participate in an Upcoming Investor Conference
November 25, 2024
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
November 6, 2024
Nkarta to Participate in Upcoming Investor Conference
September 2, 2024
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 12, 2024
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
July 23, 2024
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
July 15, 2024
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
June 26, 2024
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
June 12, 2024
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
May 8, 2024
Nkarta to Participate in Upcoming Investor Conferences
April 2, 2024
Nkarta Announces Pricing of $240 Million Underwritten Offering
March 24, 2024
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
March 20, 2024
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
December 8, 2023
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 8, 2023
Nkarta to Participate at Upcoming Investor Conferences
November 6, 2023
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
October 16, 2023
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
October 15, 2023
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 9, 2023
Nkarta to Participate at Upcoming Investor Conference
August 2, 2023
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
July 4, 2023
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
June 26, 2023
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
June 25, 2023
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
June 9, 2023
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
May 10, 2023
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
May 10, 2023
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
April 16, 2023
Nkarta Announces Departure of Chief Financial & Business Officer
March 29, 2023
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
March 15, 2023